In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

the potential of BDTX-1535 to address the unmet medical need for newly diagnosed NSCLC patients with non-classical EGFR mutations and benefit patients with NSCLC across multiple lines of therapy, the ...